Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

aptihealth Raises $50 Million Series B to Scale Higher Acuity Behavioral Healthcare Services


BOSTON, Nov. 17, 2021 /PRNewswire/ -- aptihealth, the first tech-driven behavioral health provider built to transform higher acuity care, today announced a $50 million Series B funding round from Takeda Digital Ventures, Pivotal Life Sciences, Vista Credit Partners, Olive Tree Ventures, Claritas Capital, and What If Ventures. With this funding, aptihealth will expand investment in clinical science, technology, and services that make it easy, effective, and efficient for patients, providers, community organizations, and health plans to work together securely at scale.

Providing health plan and health system customers with integrated workflow and care management capabilities, aptihealth streamlines patient referral and engagement. Proprietary diagnostics and evidenced-based care protocols meet patients' psychiatric and psychosocial needs with precise, personalized care from collaborative teams of behavioral, medical, and community resources. This results in substantial impact on the most important behavioral health drivers of outcomes and cost.

Headquartered in Boston, MA, aptihealth is in the process of relocating to new offices in the Seaport District. It also maintains a presence in Troy, NY where the company was founded. Since its launch in 2018, this most recent funding round is the company's largest to-date, and brings the total amount raised to $65 million. In four years, aptihealth has grown significantly, employing more than 120 and signing 27 health plans, health systems, and physician practice customers.

"There's an urgent need to better address higher acuity behavioral health conditions that affect tens of millions of people each year," said Dan Pickett, CEO of aptihealth. "With the patient at the center, we are redesigning care by empowering comprehensive care teams with unprecedented data, insights, and digital tools to improve efficacy and efficiency. This drives aptihealth's ability to attract the most talented providers, who in turn are achieving the highest levels of patient satisfaction, clinical quality, and outcomes. The result is increased access, better care, and lower costs. We are thrilled to partner with our customers and this exceptional group of investors to transform behavioral healthcare."        

The aptihealth platform enables seamless access for patients at any point-of-care, including referrals from physician visits, discharge from the emergency department or inpatient units, mobile web self sign-up, and proactive engagement in rising risk situations. Once engaged, aptihealth's platform intelligently integrates multidisciplinary care teams through workflow best practices and data insights to enable the right care at the right time. Patients benefit from aptihealth's modern design, fast and flexible access to care, and intuitive experience. Providers benefit from aptihealth's robust capabilities in accessing patients and using outcomes-based data management tools to support personalized care delivery.

"Takeda Digital Ventures' investment in aptihealth advances our mission to partner with companies that offer life-changing care through cutting edge innovation," said Bruce Meadows, Managing Partner at Takeda Digital Ventures. "aptihealth's virtual first care model does just that?providing precise, personalized care that substantially improves clinical quality and outcomes while increasing value for payers. We are energized by Dan and the team and believe aptihealth is positioned to become the leader in higher acuity behavioral healthcare."

Locust Walk served as transaction adviser to aptihealth.

About aptihealth
aptihealth is the first tech-driven behavioral health provider built to transform higher acuity care. Its platform provides population-precise programs that connect medical providers, behavioral health specialists, behavioral health prescribers, and patients with its proprietary screening, assessment, and treatment management protocols. aptihealth's digital platform provides a seamless and effective approach to virtual, intelligent, and comprehensive care that helps patients get better faster. Learn more at: www.aptihealth.com.

About Takeda Digital Ventures
Takeda Digital Ventures (TDV) is the digital health venture arm of Takeda, a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by a commitment to patients, people and the planet. Takeda Digital Ventures invests in companies that are using digital technologies to improve patient outcomes and improve delivery of care in areas that contribute to Takeda's data and digital transformation. Learn more at: www.takeda.com/tdv.

SOURCE aptihealth


These press releases may also interest you

15 jan 2022
Core One Labs Inc. , , ("Core One" or the "Company") is pleased to announce, as a follow up to the press release dated January 10, that Dr. Robert E.W. Hancock, the Company's Chairman, and CEO of its wholly owned subsidiary Vocan Biotechnologies...

15 jan 2022
Vial announces that in conjunction with the 2022 Winter Clinical Dermatology conference it will host an Advisory Board with leading research sites to discuss the challenges in clinical research with a focus on improving speed and quality of trials in...

15 jan 2022
WHAT: HairClub, with our Miami Heat partner, is donating a once-in-a-lifetime all-inclusive suite night and 200 tickets to a deserving selection of community-driven centers and organizations around South Florida. WHO/WHEN: As part of HairClub's...

15 jan 2022
In the news release, Color Street Foundation Pledges $1M to March of Dimes to Improve Maternal and Infant Health, issued 11-Jan-2022 by Color Street over PR Newswire, we are advised by the company that the "Color Street Foundation" hyperlink in...

15 jan 2022
Zymeworks Inc. , a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported, as required by the New York Stock Exchange Listed Company Manual Rule 303A.08 (the "NYSE Rule"), an equity inducement award to Mr....

15 jan 2022
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced results from a patient satisfaction questionnaire in the long-term, open-label...



News published on 17 november 2021 at 07:00 and distributed by: